In Alzheimer’s disease research, mutations in the amyloid precursor protein (APP) gene are closely linked to the onset of the disease.748,749 ALN-APP is a novel RNAi therapeutic developed by Alnylam using proprietary C16-siRNA conjugation technology that targets APP for AD treatment. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.